ArticleBlood advances2023

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations.

Matilde Slot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.